Latest news and press releases about ADMA Biologics, Inc. (ADMA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally.
Price
| Price | $8.90 |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 12.55 |
| Price / Book | 5.05 |
| EV / EBITDA | 21.93 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 30.78% |
| Return on Invested Capital | 27.57% |
| Return on Assets | 23.54% |
| Gross Margin | 64.71% |
| Operating Margin | 42.26% |
| Net Margin | 32.98% |
Related companies: ACAD · BLTE · CRNX · DYN · LGND · MIRM · PRAX
Explore sector: Healthcare · Biotechnology
More sections of ADMA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks